Relationship between oxidized LDL, IgM, and igg autoantibodies to ox-ldl levels with recurrent cardiovascular events in swedish patients with previous myocardial infarction

Angiology

Volumn 65, Issue 10, 2014, Pages 932-936

  Crisby, M ^a   Henareh, L ^a   Agewall, Stefan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

biomarkers; cardiovascular events; IgM and IgG MDA LDL autoantibodies; myocardial infarction; oxidized LDL

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; MALONALDEHYDE; MALONDIALDEHYDE MODIFIED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEART REINFARCTION; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SUDDEN CARDIAC DEATH; SWEDISH CITIZEN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; HEART INFARCTION; MIDDLE AGED; SWEDEN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; SWEDEN;

EID: 84908884330     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713512720     Document Type: Article

References (31)

1. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011 ; 9 (5). 533-571
2. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988 ; 260 (13). 1917-1921
3. Anber V, Millar JS, Mcconnel M, Shepherd J, Packard CJ. Interaction of very low-density, intermediate-density and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 1997 ; 17 (11). 2507-2514
4. Krauss RM. Atherogenic lipoprotein phenotype and diet-gene interactions. J Nutr. 2001 ; 131 (2). 340S - 343S
5. Nielsen LB. Transfer of low-density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis. 1996 ; 123 (1-2). 1-15
6. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989 ; 86 (4). 1372-1376
7. Tsimikas S, Glass C, Steinberg D Molecular Basis of Cardiovascular Disease: A Companion to Braunwald's Heart Disease. KR Chien, ed. Philadelphia: W.B. Saunders Company ; 2004: 385-413.
8. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994 ; 14 (1). 32-40
9. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol. 1999 ; 6 (1 pt 1). 41-53
10. Navab M, Ananthramaiah GM, Reddy ST, et al. Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004 ; 45 (6). 993-1007
11. Matsumoto T, Takashima H, Ohira N, et al. Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol. 2004 ; 44 (2). 451-457
12. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005 ; 353 (1). 46-57
13. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study. Arterioscler Thromb Vasc Biol. 2003 ; 23 (8). 1444-1448
14. Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002 ; 22 (4). 662-666
15. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004 ; 53 (4). 1068-1073
16. Sjogren P, Basu S, Rosell M, et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005 ; 25 (12). 2580-2586
17. Crisby M, Kublickiene K, Henareh L, Agewall S. Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease. Heart Vessels. 2009 ; 24 (2). 90-95
18. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002 ; 22 (10). 1649-1654
19. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 ; 36 (3). 959-969
20. Palinski W, Horkko S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996 ; 98 (3). 800-814
21. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003 ; 41 (3). 360-370
22. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Ylä-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000 ; 20 (1). 204-209
23. Palinski W, Miller ER, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 1995 ; 92 (3). 821-825
24. Tsimikas S, Palinski W, Witztum JL. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor deficient mice. Arterioscl Thromb Vasc Biol. 2001 ; 21 (1). 95-100
25. Ravandi A, Boekholdt SM, Mallat Z, et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011 ; 52 (10). 1829-1836
26. Hörkkö S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999 ; 103 (1). 117-128
27. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 ; 110 (11). 1406-1412
28. Tsimikas S, Willeit P, Willeit J, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012 ; 60 (21). 2218-2229
29. Shimada K, Mokuno H, Matsunaga E, et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004 ; 174 (2). 343-347
30. Tsimikas S, Miyanohara A, Hartvigsen K, et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol. 2011 ; 58 (16). 1715-1727
31. Faria-Neto JR, Chyu KY, Li X, et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis. 2006 ; 189 (1). 83-90